Skip to main content
Erschienen in: AIDS and Behavior 10/2015

01.10.2015 | Original Paper

Cost and Threshold Analysis of Positive Charge, a Multi-site Linkage to HIV Care Program in the United States

verfasst von: Jeeyon Janet Kim, Cathy Maulsby, Rose Zulliger, Kriti Jain, Vignetta Charles, Maura Riordan, Melissa Davey-Rothwell, David R. Holtgrave, The Positive Charge Intervention Team

Erschienen in: AIDS and Behavior | Ausgabe 10/2015

Einloggen, um Zugang zu erhalten

Abstract

Positive Charge (PC) is a linkage to HIV care initiative implemented by AIDS United with sites in New York, Chicago, Louisiana, North Carolina, and the San Francisco/Bay Area. This study employed standard methods of cost and threshold analyses, as recommended by the US Panel on Cost-effectiveness in Health and Medicine, to calculate cost-saving and cost effective thresholds of the initiative. The overall societal cost of the linkage to care programs ranged from $48,490 to $370,525. The study found that PC’s five unique evidence-based linkage to care programs have relatively low costs per client served and highly achievable cost-saving and cost-effectiveness thresholds. The findings from this study suggest that HIV linkage to care programs have the potential to be a highly productive use of public health resources.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Centers for Disease Control and Prevention. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 dependent areas—2012. HIV Surveillance Supplemental Report 2014;19(3). Centers for Disease Control and Prevention. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 dependent areas—2012. HIV Surveillance Supplemental Report 2014;19(3).
3.
Zurück zum Zitat Centers for Disease Control and Prevention. HIV Surveillance Report. 2012;24. Centers for Disease Control and Prevention. HIV Surveillance Report. 2012;24.
4.
Zurück zum Zitat Gardner EM, McLees MP, Steiner JF, Del Rio C, Burman WJ. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis. 2011;52:793–800.PubMedCentralCrossRefPubMed Gardner EM, McLees MP, Steiner JF, Del Rio C, Burman WJ. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis. 2011;52:793–800.PubMedCentralCrossRefPubMed
5.
Zurück zum Zitat Althoff KN, Gange SJ, Klein MB, Brooks JT, Hogg RS, Bosch RJ, et al. Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis. 2010;50(11):1512–20.PubMedCentralCrossRefPubMed Althoff KN, Gange SJ, Klein MB, Brooks JT, Hogg RS, Bosch RJ, et al. Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis. 2010;50(11):1512–20.PubMedCentralCrossRefPubMed
6.
Zurück zum Zitat Hall HI, Frazier EL, Rhodes P, Holtgrave DR, et al. Differences in human immunodeficiency virus care and treatment among subpopulations in the United States. JAMA Intern Med. 2013;173(14):1337–44.CrossRefPubMed Hall HI, Frazier EL, Rhodes P, Holtgrave DR, et al. Differences in human immunodeficiency virus care and treatment among subpopulations in the United States. JAMA Intern Med. 2013;173(14):1337–44.CrossRefPubMed
7.
Zurück zum Zitat Creese A, Floyd K, Alban A, Guinness L. Cost-effectiveness of HIV/AIDS interventions in Africa: a systematic review of the evidence. Lancet. 2002;359(9318):1635–42.CrossRefPubMed Creese A, Floyd K, Alban A, Guinness L. Cost-effectiveness of HIV/AIDS interventions in Africa: a systematic review of the evidence. Lancet. 2002;359(9318):1635–42.CrossRefPubMed
8.
Zurück zum Zitat Hogan DR, Baltussen R, Hayashi C, Lauer JA, Salomon JA. Cost effectiveness analysis of strategies to combat HIV/AIDS in developing countries. BMJ. 2005;331(7530):1431–7.PubMedCentralCrossRefPubMed Hogan DR, Baltussen R, Hayashi C, Lauer JA, Salomon JA. Cost effectiveness analysis of strategies to combat HIV/AIDS in developing countries. BMJ. 2005;331(7530):1431–7.PubMedCentralCrossRefPubMed
9.
Zurück zum Zitat Walker D. Cost and cost-effectiveness of HIV/AIDS prevention strategies in developing countries: is there an evidence base? Health Policy Plan. 2003;18:4–17.CrossRefPubMed Walker D. Cost and cost-effectiveness of HIV/AIDS prevention strategies in developing countries: is there an evidence base? Health Policy Plan. 2003;18:4–17.CrossRefPubMed
10.
Zurück zum Zitat Kessler J, Myers JE, Nucifora KA, Mensah N, Kowalski A, et al. Averting HIV infections in New York City: a modeling approach estimating the future impact of additional behavioral and biomedical HIV prevention strategies. PLoS One. 2013;8(9):e73269.PubMedCentralCrossRefPubMed Kessler J, Myers JE, Nucifora KA, Mensah N, Kowalski A, et al. Averting HIV infections in New York City: a modeling approach estimating the future impact of additional behavioral and biomedical HIV prevention strategies. PLoS One. 2013;8(9):e73269.PubMedCentralCrossRefPubMed
11.
Zurück zum Zitat Long EF, Brandeau ML, Owens DK. The cost-effectiveness and population outcomes of expanded HIV screening and antiretroviral treatment in the United States. Ann Intern Med. 2010;153:778–89.PubMedCentralCrossRefPubMed Long EF, Brandeau ML, Owens DK. The cost-effectiveness and population outcomes of expanded HIV screening and antiretroviral treatment in the United States. Ann Intern Med. 2010;153:778–89.PubMedCentralCrossRefPubMed
12.
Zurück zum Zitat Weaver MR, Conover CJ, Proescholdbell RJ, Arno PS, Ang A, Uldall KK, Ettner SL. Cost-effectiveness analysis of integrated care for people with HIV, chronic mental illness and substance abuse disorders. J Ment Health Policy Econ. 2009;12(1):33–46.PubMed Weaver MR, Conover CJ, Proescholdbell RJ, Arno PS, Ang A, Uldall KK, Ettner SL. Cost-effectiveness analysis of integrated care for people with HIV, chronic mental illness and substance abuse disorders. J Ment Health Policy Econ. 2009;12(1):33–46.PubMed
13.
Zurück zum Zitat Gardner LI, Metsch LR, Anderson-Mahoney P, Loughlin AM, Del Rio C, Strathdee S, et al. Efficacy of a brief case management intervention to link recently diagnosed HIV-infected persons to care. Aids. 2005;19(4):423–31.CrossRefPubMed Gardner LI, Metsch LR, Anderson-Mahoney P, Loughlin AM, Del Rio C, Strathdee S, et al. Efficacy of a brief case management intervention to link recently diagnosed HIV-infected persons to care. Aids. 2005;19(4):423–31.CrossRefPubMed
14.
Zurück zum Zitat Gold MR, Seigel JE, Russel LB, Weinstein MC, editors. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996. Gold MR, Seigel JE, Russel LB, Weinstein MC, editors. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996.
15.
Zurück zum Zitat Holtgrave DR. Handbook of economic evaluation of HIV prevention programs. New York: Plenum Publishing Corporation; 1998.CrossRef Holtgrave DR. Handbook of economic evaluation of HIV prevention programs. New York: Plenum Publishing Corporation; 1998.CrossRef
16.
Zurück zum Zitat Holtgrave DR, Briddell K, Little E, Bendixen AV, Hooper M, Kidder DP, et al. Cost and threshold analysis of housing as an HIV prevention intervention. AIDS Behav. 2007;11(2):162–6.CrossRefPubMed Holtgrave DR, Briddell K, Little E, Bendixen AV, Hooper M, Kidder DP, et al. Cost and threshold analysis of housing as an HIV prevention intervention. AIDS Behav. 2007;11(2):162–6.CrossRefPubMed
17.
Zurück zum Zitat Gorsky RD. A method to measure the costs of counseling for HIV prevention. Public Health Rep. 1996;111(Suppl 1):115.PubMedCentralPubMed Gorsky RD. A method to measure the costs of counseling for HIV prevention. Public Health Rep. 1996;111(Suppl 1):115.PubMedCentralPubMed
18.
Zurück zum Zitat Holtgrave DR, Pinkerton SD. Updates of cost of illness and quality of life estimates for use in economic evaluations of HIV prevention programs. JAIDS. 1997;16(1):54–62.PubMed Holtgrave DR, Pinkerton SD. Updates of cost of illness and quality of life estimates for use in economic evaluations of HIV prevention programs. JAIDS. 1997;16(1):54–62.PubMed
19.
Zurück zum Zitat Hutchinson AB, Farnham PG, Dean HD, Ekwueme DU, DelRio C, Kamimoto L, Kellerman SE. The economic burden of HIV in the United States in the era of highly active antiretroviral therapy: evidence of continuing racial and ethnic differences. JAIDS. 2006;43(4):451–7.PubMed Hutchinson AB, Farnham PG, Dean HD, Ekwueme DU, DelRio C, Kamimoto L, Kellerman SE. The economic burden of HIV in the United States in the era of highly active antiretroviral therapy: evidence of continuing racial and ethnic differences. JAIDS. 2006;43(4):451–7.PubMed
20.
Zurück zum Zitat Pinkerton SD, Johnson-Masotti AP, Holtgrave DR, Farnham PG. Using cost-effectiveness league tables to compare interventions to prevent sexual transmission of HIV. AIDS. 2011;15(7):917–28.CrossRef Pinkerton SD, Johnson-Masotti AP, Holtgrave DR, Farnham PG. Using cost-effectiveness league tables to compare interventions to prevent sexual transmission of HIV. AIDS. 2011;15(7):917–28.CrossRef
21.
Zurück zum Zitat Schackman BR, Gebo KA, Walensky RP, et al. The lifetime cost of current Human Immunodeficiency Virus care in the United States. Med Care. 2006;44(11):990–7.CrossRefPubMed Schackman BR, Gebo KA, Walensky RP, et al. The lifetime cost of current Human Immunodeficiency Virus care in the United States. Med Care. 2006;44(11):990–7.CrossRefPubMed
22.
Zurück zum Zitat Farnham PG, Holtgrave DR, Gopalappa C, Hutchinson AB. Lifetime costs and QALYs saved from HIV prevention in the test and treat era letter to the editor. JAIDS. 2013;64(2):e15–8.PubMed Farnham PG, Holtgrave DR, Gopalappa C, Hutchinson AB. Lifetime costs and QALYs saved from HIV prevention in the test and treat era letter to the editor. JAIDS. 2013;64(2):e15–8.PubMed
23.
Zurück zum Zitat Walensky RP, Freedberg KA, Weinstein MC, Paltiel AD. Cost-effectiveness of HIV testing and treatment in the United States. Clin Infect Dis. 2007;45(Suppl 4):S248–54.PubMedCentralCrossRefPubMed Walensky RP, Freedberg KA, Weinstein MC, Paltiel AD. Cost-effectiveness of HIV testing and treatment in the United States. Clin Infect Dis. 2007;45(Suppl 4):S248–54.PubMedCentralCrossRefPubMed
24.
Zurück zum Zitat Cohen DA, Wu SY, Farley TA. Comparing the cost-effectiveness of HIV prevention interventions. JAIDS. 2004;37:1404–14.PubMed Cohen DA, Wu SY, Farley TA. Comparing the cost-effectiveness of HIV prevention interventions. JAIDS. 2004;37:1404–14.PubMed
25.
Zurück zum Zitat White House Office of National AIDS Policy. National HIV/AIDS Strategy for the United States. Washington: White House Office of National AIDS Policy; 2010. White House Office of National AIDS Policy. National HIV/AIDS Strategy for the United States. Washington: White House Office of National AIDS Policy; 2010.
26.
Zurück zum Zitat Skarbinski J, Rosenberg E, Paz-Bailey G, Hall HI, Rose CE, Viall AH, Fagan JL, Lansky A, Mermin JK. Human Immunodeficiency Virus Transmission at Each Step of the Care Continuum in the United States. JAMA Intern Med. 2015;175(4):588–96.CrossRefPubMed Skarbinski J, Rosenberg E, Paz-Bailey G, Hall HI, Rose CE, Viall AH, Fagan JL, Lansky A, Mermin JK. Human Immunodeficiency Virus Transmission at Each Step of the Care Continuum in the United States. JAMA Intern Med. 2015;175(4):588–96.CrossRefPubMed
28.
29.
Zurück zum Zitat Paltiel AD, Stinnett AA. Resource allocation and the funding of HIV prevention. In: Holtgrave DR, editor. Handbook of economic evaluation of HIV prevention programs. New York: Plenum Press; 1998. p. 135–52.CrossRef Paltiel AD, Stinnett AA. Resource allocation and the funding of HIV prevention. In: Holtgrave DR, editor. Handbook of economic evaluation of HIV prevention programs. New York: Plenum Press; 1998. p. 135–52.CrossRef
30.
Zurück zum Zitat Rauner MS, Brandeau ML. AIDS policy odeling for the 21st century: an overview of key issues. Health Care Manag Sci. 2001;4:165–80.CrossRefPubMed Rauner MS, Brandeau ML. AIDS policy odeling for the 21st century: an overview of key issues. Health Care Manag Sci. 2001;4:165–80.CrossRefPubMed
31.
Zurück zum Zitat Holtgrave DR. HIV prevention, cost-utility analysis, and race/ethnicity: methodological considerations and recommendations. Med Decis Making. 2004;24(2):181–91.CrossRefPubMed Holtgrave DR. HIV prevention, cost-utility analysis, and race/ethnicity: methodological considerations and recommendations. Med Decis Making. 2004;24(2):181–91.CrossRefPubMed
32.
Zurück zum Zitat Pinkerton SD, Johnson-Masotti AP, Holtgrave DR, Farnham PG. Using cost-effectiveness league tables. Pinkerton SD, Johnson-Masotti AP, Holtgrave DR, Farnham PG. Using cost-effectiveness league tables.
Metadaten
Titel
Cost and Threshold Analysis of Positive Charge, a Multi-site Linkage to HIV Care Program in the United States
verfasst von
Jeeyon Janet Kim
Cathy Maulsby
Rose Zulliger
Kriti Jain
Vignetta Charles
Maura Riordan
Melissa Davey-Rothwell
David R. Holtgrave
The Positive Charge Intervention Team
Publikationsdatum
01.10.2015
Verlag
Springer US
Erschienen in
AIDS and Behavior / Ausgabe 10/2015
Print ISSN: 1090-7165
Elektronische ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-015-1124-9

Weitere Artikel der Ausgabe 10/2015

AIDS and Behavior 10/2015 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.